Testing the genetic signal
Fetal haemoglobin usually falls after birth; when it remains high in adulthood, it can ease symptoms of sickle cell disease and beta thalassaemia. A peer-reviewed Nature study found 91 independent genetic signals associated with its level in 28,279 people. One signal tracked with lower BACH2 activity and higher fetal haemoglobin. Those human data are a starting point for choosing a regulatory pathway to investigate, rather than a treatment trial.[1]
When researchers reduced or inhibited BACH2 in cells, fetal-haemoglobin production rose. They showed that lifting BACH2 repression allowed another regulator, NRF2, to bind more strongly near the gamma-globin genes. This direct intervention makes the mechanism more persuasive than the genetic association alone. A higher laboratory measure in cells, however, says nothing yet about whether a patient’s painful crises or other outcomes improve.[1]
The steps toward treatment
The DNA binding sequences for BACH2 and NRF2 partly overlap. The team edited them separately and shifted gamma-globin activity in different directions; the route also operated independently of the established BCL11A regulator. That distinction makes it a meaningful target beyond existing approaches. Yet no study here tested which cells to alter, how strongly, or for how long in patients. Effects on BACH2’s other functions would also belong in a clinical safety assessment.[1]
The strength of the finding lies in following an association across 28,279 people with a cellular test of mechanism. An alternative is not fully closed: other effects in the same genetic region could contribute to the human signal. Whether gamma-globin activation lasts, and whether it becomes a measurable benefit in a patient’s life, are questions for separate research. The development today is a more clearly drawn route to test, not a new medicine ready for use.[1]